Tamoxifen Alternatives Compared
Tamoxifen | Pembrolizumab | Kisqali |
|
---|
Tamoxifen | Pembrolizumab | Kisqali (ribociclib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Breast Cancer - Adjuvant, Breast Cancer - Male, Breast Cancer, Breast Cancer - Metastatic, Breast Cancer - Palliative, Breast Cancer - Prevention, McCune-Albright Syndrome, Precocious... View more |
Prescription only
Prescribed for Bladder Cancer, Breast Cancer, Cervical Cancer, Biliary Tract Tumor, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more |
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. Kisqali may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||||||||||
More about Tamoxifen | More about Pembrolizumab | More about Kisqali (ribociclib) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Tamoxifen has an average rating of 5.5 out of 10 from a total of 96 ratings on Drugs.com. 31% of reviewers reported a positive effect, while 29% reported a negative effect. |
Pembrolizumab has an average rating of 4.6 out of 10 from a total of 233 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 54% reported a negative effect. |
Kisqali has an average rating of 8.6 out of 10 from a total of 26 ratings on Drugs.com. 84% of reviewers reported a positive effect, while 4% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: tamoxifen side effects in more detail. |
See also: pembrolizumab side effects in more detail. |
See also: Kisqali side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
Lower cost generic |
N/A |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all tamoxifen prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Kisqali prices |
||||||||||||||||
Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Soltamox | Keytruda |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
231 hours |
624 hours |
54.7 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 417 drugs are known to interact with tamoxifen:
|
A total of 16 drugs are known to interact with pembrolizumab:
|
A total of 711 drugs are known to interact with Kisqali:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
December 30, 1977 |
N/A |
March 13, 2017 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
|||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
|
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.